Shares of PI Industries were down 8 per cent to Rs 2,756 on the BSE in Tuesday’s intra-day trade after the company terminated the agreement related to acquisition on slump sale of Ind-Swift Laboratories (ISLL). This is due to ISLL has not been able to complete several of the pre-agreed conditions precedents.

“Given non-fulfilment and also disagreement on some of the pre-agreed conditions, the company has decided not to pursue the transaction further,” PI Industries said in a statement.

• Indian Farmers Switch Crops Amid Rising Temperatures
• Lutnick’s Firm in Talks with Tether for $2 Billion Bitcoin Lending Deal
• India Criticizes COP29 Climate Deal
• Agarwal Toughened Glass India IPO GMP, Open/Close Date & Minimum Investment
• Co-living Startup Truliv Expands into Bengaluru

PIs’ strategy to strengthen presence in custom synthesis exports through diversification into adjacencies, including pharma, remains intact. The R&D establishment within PI remains attuned to developing and scaling multiple advanced technologies, processes, and platforms to execute its long-term strategy, the company said. “PI Industries will continue to evaluate other M&A opportunities that are aligned to it strategic direction with the intention to create a differentiated scale play in pharma,” it added.